Jasper Therapeutics, Inc. — All Filings
431 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
10-Q/A
144
25-NSE
3
3/A
4
424B3
424B4
424B5
425
8-A12B
8-K
8-K/A
ARS
CERT
CORRESP
DEF 14A
DEFA14A
DRS
EFFECT
NT 10-Q
POS AM
PRE 14A
S-1
S-1/A
S-3
S-4
S-4/A
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SCHEDULE 13G | — | 0001104659-26-019751 | Feb 25, 2026 | — |
| 4 | — | 0001213900-26-014244 | Feb 10, 2026 | Feb 6, 2026 |
| SCHEDULE 13G/A | — | 0001636587-26-000002 | Jan 26, 2026 | — |
| 8-K | CURRENT REPORT | 0001213900-26-002329 | Jan 8, 2026 | — |
| 8-K | CURRENT REPORT | 0001213900-26-002185 | Jan 7, 2026 | Jan 2, 2026 |
| 4 | — | 0001213900-26-001383 | Jan 5, 2026 | Jan 2, 2026 |
| 4 | — | 0001213900-26-001385 | Jan 5, 2026 | Jan 2, 2026 |
| 4 | — | 0001213900-26-001382 | Jan 5, 2026 | Jan 2, 2026 |
| 8-K | CURRENT REPORT | 0001213900-25-116943 | Dec 2, 2025 | — |
| SCHEDULE 13G | — | 0001636587-25-000064 | Dec 2, 2025 | — |
| SCHEDULE 13G/A | — | 0001765710-25-000005 | Nov 14, 2025 | — |
| SCHEDULE 13G | — | 0001897612-25-000546 | Nov 14, 2025 | — |
| SCHEDULE 13G/A | — | 0000919574-25-006584 | Nov 12, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-107874 | Nov 10, 2025 | — |
| 10-Q | QUARTERLY REPORT | 0001213900-25-107884 | Nov 10, 2025 | Sep 30, 2025 |
| 4 | — | 0001213900-25-091105 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001213900-25-091104 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001213900-25-091096 | Sep 24, 2025 | Sep 22, 2025 |
| 4 | — | 0001213900-25-091099 | Sep 24, 2025 | Sep 22, 2025 |
| SCHEDULE 13D/A | — | 0000921895-25-002600 | Sep 23, 2025 | — |
| 424B5 | PROSPECTUS SUPPLEMENT | 0001213900-25-089581 | Sep 19, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-089584 | Sep 19, 2025 | Sep 18, 2025 |
| 424B5 | PROSPECTUS SUPPLEMENT | 0001213900-25-089025 | Sep 18, 2025 | — |
| 10-Q | QUARTERLY REPORT | 0001213900-25-075635 | Aug 13, 2025 | Jun 30, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-075678 | Aug 13, 2025 | — |
| SCHEDULE 13G/A | — | 0002052113-25-003206 | Jul 17, 2025 | — |
| SCHEDULE 13G | — | 0000919574-25-004068 | Jul 11, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-062194 | Jul 9, 2025 | Jul 8, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-061632 | Jul 7, 2025 | — |
| 4 | — | 0001213900-25-061501 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061503 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061498 | Jul 3, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-061471 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061500 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061493 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061495 | Jul 3, 2025 | — |
| 4 | — | 0001213900-25-061492 | Jul 3, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-054465 | Jun 16, 2025 | Jun 14, 2025 |
| 4 | — | 0001213900-25-051729 | Jun 6, 2025 | Jun 4, 2025 |
| 4 | — | 0001213900-25-051722 | Jun 6, 2025 | Jun 4, 2025 |
| 4 | — | 0001213900-25-051724 | Jun 6, 2025 | Jun 4, 2025 |
| 4 | — | 0001213900-25-051726 | Jun 6, 2025 | Jun 4, 2025 |
| DEF 14A | DEFINITIVE PROXY STATEMENT | 0001213900-25-045086 | May 19, 2025 | Jul 3, 2025 |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-25-045090 | May 19, 2025 | — |
| ARS | FORM ARS | 0001213900-25-045091 | May 19, 2025 | Dec 31, 2024 |
| 10-Q | QUARTERLY REPORT | 0001213900-25-042011 | May 12, 2025 | Mar 31, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-042017 | May 12, 2025 | — |
| 424B5 | PROSPECTUS | 0001013762-25-002767 | Mar 26, 2025 | — |
| EFFECT | — | 9999999995-25-000800 | Mar 26, 2025 | — |
| CORRESP | — | 0001013762-25-001604 | Mar 24, 2025 | — |